What's Happening?
The FDA has announced plans to regulate 7-Hydroxymitragynine (7-OH), a compound found in kratom, due to its addictive potential. This move comes amid increasing reports of kratom addiction, with individuals experiencing severe withdrawal symptoms and life-altering consequences. Kratom, often marketed as a natural wellness supplement, has been linked to addiction similar to opioids. The FDA's action aims to classify 7-OH as an illicit substance, pending DEA approval, while kratom products remain legal in most states. The announcement follows a class-action lawsuit against Botanic Tonics, a company selling kratom products.
AD
Why It's Important?
The FDA's decision to target 7-OH reflects growing concerns about the safety and regulation of kratom products, which are widely available and marketed as natural supplements. This regulatory action could lead to stricter controls and increased awareness of the risks associated with kratom use. It highlights the need for comprehensive public health strategies to address emerging substance abuse issues and protect consumers. The move may influence industry practices and consumer perceptions, potentially reducing the prevalence of kratom-related addiction.
